#59 - What’s next for obesity care in the GLP-1 era - Kim Boyd - Weight Watchers

What if we treated obesity not as a failure of willpower, but as the complex, chronic medical condition it truly is?

With over half of the global adult population expected to be living with overweight or obesity by 2035, according to the World Obesity Federation, traditional "eat less, exercise more" advice has proven fundamentally insufficient. The widespread arrival of GLP-1 receptor agonists has marked a dramatic shift in metabolic care, offering unprecedented efficacy in weight management, diabetes treatment, and cardiovascular risk reduction.

Yet, as these therapies gain global momentum, critical questions remain around their long-term management, side effect mitigation, and equitable access.

Among those leading the charge toward comprehensive, patient-centered care is Dr. Kim Boyd, Chief Medical Officer at Weight Watchers. A primary care doctor trained in integrative medicine and an early leader at One Medical, Kim sits at the intersection of modern pharmacology, behavioral science, and digital health technology.

In this episode of Impulse, Kim breaks down the pathophysiology of obesity as a chronic disease associated with over 200 health conditions across the cardiovascular, renal, and metabolic (CVRM) spectrum. We explore the rapidly expanding therapeutic landscape—from established injectables like Wegovy and Zepbound to oral formulations, amylin combinations, and muscle-sparing agents in the pipeline. Kim shares why medications alone are not a magic bullet and details how companion digital programs, strength training, and tailored nutrition are essential to preserving muscle functionality and achieving lasting health outcomes.

We also discuss how digital health tools and AI can distill overwhelming physiological data into daily actionable habits, the challenges of global health coverage and pricing dynamics, and the future of sustainable obesity management.

A timely and eye-opening conversation on the evolution of metabolic health and the future of comprehensive obesity care!

Timeline:

00:00:00 - Kim's background and role as Chief Medical Officer at Weight Watchers

00:04:15 - Redefining obesity as a chronic medical condition

00:15:05 - Mapping the therapeutic landscape: GLP-1s, oral formulations, and pipeline agents

00:24:00 - Managing side effects, preserving muscle functionality, and the role of companion care